A Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations
A Randomized, Open-label, Cross-over Clinical Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations in Adult Smokers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Having smoked ≥10 manufactured cigarettes per day for at least the last year
- Expired carbon monoxide level of >10 ppm at screening
- Tested positive for urinary cotinine (≥500 ng/mL)
Exclusion Criteria:
- Known or suspected hypersensitivity to any component of the e-liquid formulations
- Taking or receiving prescription smoking cessation medicines
- Willing or considering to stop smoking
- Smokers who draw smoke into their mouth and throat but do not inhale
- Relevant illness history
- Body mass index (BMI) of less than 18 kg/m2 or greater than 40 kg/m2
- Breastfeeding women
- Women of child-bearing potential who were not using an accepted method of contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Conventional cigarette
The subject's preferred brand of commercially available conventional cigarette
|
Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
|
|
ACTIVE_COMPARATOR: myblu 25 mg freebase
myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
|
E-cigarette used for 10 inhalations every 30 seconds
|
|
ACTIVE_COMPARATOR: myblu 16 mg nicotine salt
myblu pod-system containing 16 mg nicotine salt tobacco flavour
|
E-cigarette used for 10 inhalations every 30 seconds
|
|
ACTIVE_COMPARATOR: myblu 25 mg nicotine salt
myblu pod-system containing 25 mg nicotine salt tobacco flavour
|
E-cigarette used for 10 inhalations every 30 seconds
|
|
ACTIVE_COMPARATOR: myblu 40 mg nicotine salt
myblu pod-system containing 40 mg nicotine salt tobacco flavour
|
E-cigarette used for 10 inhalations every 30 seconds
|
|
ACTIVE_COMPARATOR: blu PRO 48 mg nicotine salt
blu PRO open-system containing 48 mg nicotine salt tobacco flavour
|
E-cigarette used for 10 inhalations every 30 seconds
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nicotine pharmacokinetics Cmax
Time Frame: 30 minutes following the start of product use (12 measurements over the period)
|
Mean maximum plasma nicotine concentration (Cmax)
|
30 minutes following the start of product use (12 measurements over the period)
|
|
Nicotine pharmacokinetics Tmax
Time Frame: 30 minutes following the start of product use (12 measurements over the period)
|
Median time to maximum plasma nicotine concentration (Tmax)
|
30 minutes following the start of product use (12 measurements over the period)
|
|
Nicotine pharmacokinetics AUC0-30
Time Frame: 30 minutes following the start of product use (12 measurements over the period)
|
Mean area under the plasma nicotine concertation-time curve, from time zero to 30 minutes (AUC0-30)
|
30 minutes following the start of product use (12 measurements over the period)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective effects questionnaire
Time Frame: 20 minutes after the start of product use
|
Likert-type scale with responses ranging from 1 (not at all) to 7 (extremely).
The following questions were asked: Did it make you dizzy?
Did it make you nauseous?
Did you enjoy it?
Did it relieve the urge to smoke?
Was it enough nicotine?
Was it too much nicotine?
|
20 minutes after the start of product use
|
|
Incidence and nature of any adverse events (AE)
Time Frame: Through study completion, 6 days
|
Incidence and nature of any adverse events (AE) (Safety and Tolerability)
|
Through study completion, 6 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FON-01blu-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.